Uniquity Bio develops high‑potency monoclonal antibodies that target key drivers of inflammation, beginning with solrikitug, an anti‑TSLP antibody aimed at treating COPD, severe asthma, and eosinophilic esophagitis. Leveraging a pharma‑grade development platform and scalable manufacturing, the company advances its immunology pipeline through rapid Phase 2 trials to enable co‑development or licensing partnerships.
Funding
$300M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with chronic immune‑mediated diseases such as COPD, severe asthma, and eosinophilic esophagitis have limited or no effective biologic treatment options, leading to ongoing symptoms, disease progression, and reduced quality of life.
Solution
Uniquity Bio focuses on developing highly potent monoclonal antibodies that target key drivers of inflammation, beginning with solrikitug, an anti‑TSLP antibody. By inhibiting thymic stromal lymphopoietin, a master cytokine at the top of the inflammatory cascade, solrikitug aims to provide best‑in‑class efficacy across multiple respiratory and gastrointestinal indications. The company advances the asset through Phase 2 trials, leveraging a robust, scalable manufacturing process to accelerate development. Uniquity’s agile, pharma‑level development platform integrates rigorous scientific evaluation with rapid decision‑making to move promising immunology therapeutics toward late‑stage trials and eventual market entry.
Target Audience
Primary customers are pharmaceutical partners and biotech companies seeking to co‑develop or license advanced immunology therapeutics, as well as clinical investigators conducting trials in COPD, severe asthma, and eosinophilic esophagitis.
Features
- Anti‑TSLP monoclonal antibody (solrikitug) designed for high potency and specificity
- Clinical program spanning COPD, asthma, and eosinophilic esophagitis with ongoing Phase 2 studies
- Optimized, scalable manufacturing process to support rapid progression to late‑stage development
- Integrated dose‑optimization strategy to maximize efficacy across diverse disease phenotypes
- Experienced development team applying rigorous, pharma‑grade clinical, regulatory, and operational expertise